CAR T Therapy
Md Yuzaiful Md Yusof Yuz6Yusof
3 months ago
#ACR25 Abstr#641 Phase 1/2 CASTLE Basket Trial fully recruited N=24 (10 SLE, 9 SSc, 5 IIM). Short-term data of autologous CD19-CAR T
Zorpocabtagene-autoleucel/MB19.1:
- 22/24 high degree efficacy
- no relapse
- no high grade CRS/ICANS
*Need larger Phase prior approval @RheumNow https://t.co/sp1nieeCvl
Richard Conway RichardPAConway
3 months ago
Albach et al. CAR T-cells in D2T RA. 6 patients. Safety looks ok. ACR20 in 4/6, ACR50 in 2/6. ACPA and RF disappeared. Results maybe not as positive as we might have anticipated? @RheumNow #ACR25 Abstr#471 https://t.co/TaEVWiWsNm
Two pioneering studies presented at ACR Convergence 2025 spotlight the potential of CAR-T cell therapies to transform treatment for systemic lupus erythematosus (SLE) and other autoimmune diseases. These early findings suggest a new frontier in immune modulation and long-term disease remission.
Gabriela Martinez Zayas, MD MartinezZayasMd
3 months ago
Summary of updates in Vasculitis by Dr John Stone: 1. Anti-CD19 in IgG4Rd, 2. IL6 6R blockade in GCA/IL17i in PMR, 3. IL5RA+ ritux in EGPA. CART in AAV? @RheumNow #ACR2025 https://t.co/HxPNRE98Vl
Poster Hall